November 2024
The global research antibodies market size was estimated at US$ 1.60 billion in 2023 and is projected to grow to US$ 2.55 billion by 2033, rising at a compound annual growth rate (CAGR) of 4.90% from 2024 to 2033. The rising need for high-quality antibodies for repeatable research is one of the main factors driving the growth of the research antibody market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Because of their utility as molecular markers for precise labeling and detection, antibodies have emerged as indispensable instruments for the majority of life science study fields. In diagnostic medicine, antibodies are invaluable tools that improve the accuracy and consistency of identifying particular antigens. Researchers can take advantage of this mechanism and employ antibodies to detect the presence, or even the concentration, of particular proteins in order to aid in the diagnosis of various illnesses. They are widely employed in biomedical research, mostly in medicines, diagnostics, and many other areas, because of their great selectivity and specificity. Because of their uses in oncology, gene therapy, stem cell analysis, autoimmune disease therapy, and many other disorders, the research antibodies market is gaining popularity.
The Research Antibodies market ecosystem comprises several key components and contributors. At its core, the market includes various types of antibodies, such as monoclonal, polyclonal, and recombinant antibodies, each serving distinct research needs. Monoclonal antibodies are highly specific and produced from a single clone of cells, making them essential for precise experiments. Polyclonal antibodies, derived from multiple cell clones, offer a broader range of applications. Recombinant antibodies are engineered for enhanced specificity and functionality.
Leading companies in this sector, like Thermo Fisher Scientific, Abcam, and Bio-Rad Laboratories, play crucial roles by providing high-quality antibodies and innovative technologies. Thermo Fisher offers a broad range of antibodies and associated reagents, facilitating diverse research applications. Abcam is known for its extensive catalog and high-quality products, supporting advanced research in various fields. Bio-Rad Laboratories contributes with its expertise in antibody development and validation, ensuring reliability and performance in experimental settings.
Companies such as MilliporeSigma and Cell Signaling Technology enhance the ecosystem with specialized antibodies and advanced solutions, driving forward research and development in life sciences. Together, these players create a dynamic and collaborative environment that advances scientific discovery and innovation.
| Company Name | Integral Molecular |
| Headquarters | Pennsylvania, U.S., North America |
| Recent Development | In May 2024, Cell Surface Bio is a biotech business founded by Integral Molecular, a life sciences company with headquarters in Philadelphia. Cell Surface Bio produces antibodies for scientists and researchers in the academic and industry sectors. According to the company's website, their antibodies were developed during twenty years of investigation, learning, and testing. Scientific laboratories, whether located in drug development firms or university institutions, are anticipated to be the startup's clients. |
| Company Name | Bio-Rad Laboratories |
| Headquarters | California, U.S., North America |
| Recent Development | In March 2024, Bio-Rad Laboratories, Inc., a leading global provider of clinical diagnostics products and life science research, announced the release of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. The antibodies are specific to CTC surface markers, allowing for the sensitive and specific identification of target cell populations. This improves the investigation of tumor heterogeneity and disease development at different stages and has been validated for use with Bio-Rad's Celselect Slides Enumeration Stain Kits. |
Since today's antibody medications are so selective, side effects are becoming less frequent. Consequently, therapeutic antibodies have emerged as the most common type of newly produced pharmaceuticals in recent times. Antibodies are now the pharmaceutical market's best-selling medications for the last five years. Since new medications have been approved to treat a wide range of human diseases, including numerous malignancies as well as autoimmune, metabolic, and viral diseases, the market for therapeutic antibody medicines has grown explosively.
Strict standards are one of the things holding back the market's expansion when developing and researching antibodies in order to guarantee high-quality products. The approval of research antibody products is particularly complex because all FDA-regulated facilities must implement cGMP and aseptic processes. Products are verified on multiple factors to prevent contamination, which prolongs the approval procedure. Tight regulations imposed by animal welfare groups on the production of antibodies derived from animals could impede the expansion of the market.
Numerous breakthroughs in antibody design were made possible by technological developments in medication development and research. Antibody conjugates, bispecific or multispecific antibodies, and antibody fragments are some of the techniques that have been developed for the development of antibodies. When developing multi-targeted antibodies that can cure numerous diseases at once, antibody engineering techniques can be used to boost affinity for targets. Multifunctionalization and miniaturization are two crucial antibody production techniques that can increase the efficacy of therapeutic antibodies. Another pathway to pursue in the future may be the development of customized antibody-based vaccinations. Enhancing antibodies to target a variety of diseases, including infectious diseases and cancer, should be a key component of the future of antibody treatments.
The primary antibodies segment held the largest share of the research antibodies market in 2023. In immunoassays such as chromatin immunoprecipitation (ChIP), immunohistochemistry, western blot, ELISA, and flow cytometry, primary antibodies are typically utilized. Primary antibodies can be coupled to fluorophores or reporter enzymes for antigen detection, which makes it easier to quantify or analyze antigen expression. Primary antibodies are frequently employed in conjunction with reagents and buffers for research purposes. Any research-relevant antigen, such as proteins, peptides, polysaccharides, and other tiny molecules, can be produced as primary antibodies. Primary antibodies can also be produced to detect post-translational alterations like phosphorylation, acetylation, methylation, and glycosylation. Therefore, primary antibodies are excellent instruments for molecular analysis of living cell components and for identifying proteins that could be implicated in or contribute to disease.
For instance,
The secondary antibodies segment is estimated to grow significantly in the research antibodies market during the forecast period. Secondary antibodies recognize the primary antibody, which is attached to its antigen or protein of interest, as its target antigen. Because of their capacity to bind to a variety of antibody clones, secondary antibodies are highly useful research instruments. Secondary antibodies that are frequently utilized include those that are anti-rabbit, anti-mouse, anti-chicken or anti-goat.
For instance,
The monoclonal antibodies segment dominated the research antibodies market in 2023. An antiquated immunological instrument that is used in biotechnology, immunology, biochemistry, and applied biology is the monoclonal antibody (MAb). MAbs have recently been used extensively in clinical practice. Because of their high specificity, monoclonal antibodies (MAbs) have shown to be incredibly beneficial for basic immunological and molecular research. With even more late-stage clinical studies underway, monoclonal antibodies (MAbs) already make up one-third of all newly developed therapeutic therapies for conditions like psoriasis, arthritis, leukemia, transplant rejection, and breast cancer.
For instance,
The polyclonal antibodies segment is anticipated to have lucrative growth in the research antibodies market during the forecast period. Polyclonal antibodies are used in a variety of diagnostic procedures to identify the presence of particular antigens. One of the most important aspects of scientific study is the use of polyclonal antibodies to examine the presence and location of particular proteins within cells or tissues. They facilitate understanding of biological processes, disease mechanisms, and protein expression. Polyclonal antibodies have several uses and a diverse composition, which makes them essential for immunology, diagnosis, and treatment. They are important tools in the battle against disease because of their capacity to target several epitopes and boost the immune response. Polyclonal antibodies have a significant impact on research and treatment and will continue to do so as science and technology develop.
For instance,
The western blotting segment held the dominant share of the research antibodies market in 2023. Western blotting is the gold standard for locating and measuring a particular protein in a complicated mixture isolated from cells or tissue lysate. Western blotting (WB) is most commonly used to determine the quantity and size of proteins in a particular sample, but it has also shown promise in investigating other aspects of protein analysis.
The immunohistochemistry segment is anticipated to grow at the fastest rate in the research antibodies market during the forecast period. The potent method known as immunohistochemistry (IHC) uses the particular binding that occurs between an antibody and an antigen to identify and pinpoint certain antigens in cells and tissue. It provides important details regarding the location of proteins. Protein expression patterns have many applications in medicine and research, and they can be a valuable diagnostic tool in the identification of aberrant cells in disorders like cancer.
The rabbit segment dominated the research antibodies market in 2023. Because of their greater sensitivity and epitope specificity, rabbit monoclonal antibodies have a lower dose requirement and less off-target binding, which reduces the risk of toxicity when used therapeutically. The cross-reactivity of rabbit-derived monoclonal antibodies with human and mouse antigen epitopes is an additional benefit that helps in the preclinical assessment and characterization of mouse models used to study human disease.
The mouse segment is anticipated to grow at the fastest rate in the research antibodies market during the forecast period. In the field of biomedicine, mouse monoclonal antibodies are an invaluable instrument. Applications for them range widely, from clinical diagnosis to research. The process of creating mouse monoclonal antibodies is very easy to understand and follow.
For instance,
The oncology segment held the largest share of the research antibodies market in 2023. Hundreds of antibodies are undergoing clinical studies, and the FDA has already approved the use of more than 30 antibodies or antibody derivatives to treat cancer. Antibodies have emerged as a novel option for treating cancer. A broad variety of antigens, such as soluble proteins, cancer cell surface antigens, and effector cell receptors, can be targeted by anti-cancer antibodies. Because of their adaptability, antibodies can function through a wide range of mechanisms, including as the direct blockage of growth factors, immune system modulation, and the activation or disruption of signal transduction pathways. Furthermore, antibodies are being utilized more and more as carriers to increase the specificity of particular chemotherapeutic medications.
Additionally, WHO estimated that in 2022, there were 20 million new cases of cancer and 9.7 million cancer-related deaths. It was projected that 53.5 million people would still be alive five years after receiving a cancer diagnosis. With 2.5 million new cases worldwide, or 12.4% of all new cases, lung cancer is the most frequent malignancy. The following in incidence order were colon cancer (1.9 million cases, 9.6%), stomach cancer (970,000 cases, 4.9%), prostate cancer (1.5 million cases, 7.3%), and female breast cancer (2.3 million cases, 11.6%).
The stem cells segment is expected to grow at the fastest rate in the research antibodies market during 2024-2033. Characterizing distinct stem cells and their developed cells is a popular use of antibody-based detection techniques like immunocytochemistry and flow cytometry. The successful and quick advancement of stem cell research is largely due to the employment of high-quality antibodies. A vast collection of primary antibodies is available from Thermo Fisher Scientific for use in stem cell research.
For instance,
The academic & research institutions segment dominated the research antibodies market in 2023. Because they place a great emphasis on scientific investigation and discoveries, academic and research institutions account for the majority of research antibodies. These universities benefit from large financing, state-of-the-art equipment, and knowledgeable researchers committed to furthering their areas' understanding. The strict peer review procedure and focus on quality assurance further add to the legitimacy and dependability of antibodies made by educational and scientific establishments.
The pharmaceutical & biotechnology companies segment is expected to grow significantly in the research antibodies market during the forecast period. Antibodies are used in research by pharmaceutical and biotechnology businesses because they are essential for targeted therapeutics, medication development, and discovery. These businesses' growth in the antibody space has been driven by the increased interest in personalized treatments and precision medicine. Furthermore, the creation of innovative antibody-based therapeutics has been made possible by biotechnology developments, which has expanded investment and development in this field. This has accelerated the expansion of biotechnology and pharmaceutical businesses working in the antibody space.
North America dominated the research antibodies market in 2023. The main drivers of the market expansion are the increasing investment in the development of innovative structure-based drug patterns and the expanding attention to cancer, biomedical, and stem cells. The market need for research antibodies for the treatment of chronic diseases such blood diseases and cardiovascular diseases is driven by their rising incidence.
The demand for personalized medicine and research and development that uses cell separation for the study of biomolecules and the creation of vaccinations, antibodies, and cell treatments has surged in the U.S. due to the prevalence of chronic illnesses and other health difficulties. These elements support the expansion of the U.S. research antibodies market.
For instance,
Asia Pacific is expected to grow at the fastest rate during the forecast period. The primary drivers of market expansion are the rising number of research projects undertaken by academic institutions and the regional rollout of innovative treatments. The region's market may grow more quickly as a result of R&D efforts to find new antibodies.
Countries like India are focusing on R&D, especially in the field of biotechnology which is a major contributor to the growth of research antibodies market. The Government of India's Department of Biotechnology (DBT) is spearheading the promotion of biotechnological innovation and entrepreneurship by harnessing the potential of strategic partnerships and building capacity across the country. About INR 4,500 Cr in follow-up finance has been raised by 150 companies. The bioeconomy of the country is expected to reach $300 billion by 2030, from $137 billion in 2023.
By Product
By Type
By Technology
By Source
By Application
By End-Use
By Region
Monoclonal Antibodies (mAbs) are highly specialized antibody preparations designed to bind to a single target, and they are showing significant promise in treating both cancer and autoimmune diseases. These protein-based therapies are becoming increasingly important for managing chronic conditions. This blog explores the global market for antibody drug products, highlighting their use across various disease areas. The market is primarily segmented into four major application areas: autoimmune diseases, solid tumors, lymphoma, and leukemia. Additionally, mAbs are being explored for other conditions such as asthma, osteoporosis, and cardiovascular diseases.
With over 100 antibody products approved by the FDA and biologics representing about one-fifth of all new drug approvals annually, the robust pipeline of antibody therapies boosts the potential for higher market revenues. The growing demand for these therapies is expected to drive a significant increase in the development and market share of new antibody products.
November 2024
November 2024
November 2024
November 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts